LncRNA H19 in Cholestatic Liver Diseases
LncRNA H19 在胆汁淤积性肝病中的作用
基本信息
- 批准号:9750721
- 负责人:
- 金额:$ 53.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-25 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:ApicalBile AcidsBile Duct EpitheliumBiliaryBiological ProcessCarbon TetrachlorideCarcinomaCell Proliferation RegulationCharacteristicsCholestasisChronicCodeDataDiseaseDuctal Epithelial CellEpithelialExonsFibrosisFunctional disorderGene ExpressionGenesGenetic TranscriptionGoalsGrowthH19 geneHepaticHepatobiliaryHepatocyteHomeostasisHumanInflammationInjuryKnock-outLife Cycle StagesLigationLinkLiverLiver diseasesMaintenanceMediatingMessenger RNAMetastatic Neoplasm to the LiverMinorityMulti-Drug ResistanceMusOutputPathogenesisPatientsPhysiologicalPlayPrimary biliary cirrhosisProteinsRNA SplicingRegulationRegulator GenesReportingRoleSodiumSphingosine-1-Phosphate ReceptorStructureTaurine CholateTaurocholate SodiumTestingTissuesTranslationsUntranslated RNAUp-Regulationbasebile acid transporterbile ductcell typecholangiocytecholestatic injurycholestatic liver diseasechromatin modificationdifferential expressioneffective therapyhuman diseaseimprintknock-downliver developmentliver injurymammalian genomemouse modelnovelnovel strategiesnovel therapeuticspolypeptidepreventprimary sclerosing cholangitis
项目摘要
Cholangiopathies, such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), are
characterized by damage and dysfunction of bile duct epithelial cells (cholangiocytes). Recently, long noncoding
RNAs (lncRNAs) have been identified as a novel class of master regulators of gene expression and are linked
to many fundamental biological processes and various human diseases including various liver diseases.
However, little is known regarding the role of lncRNAs in the regulation of cholangiocyte function and
pathogenesis of hepatobiliary diseases. The overall goal of the current application is to identify the roles and
mechanisms of lncRNAs in biliary dysfunction under cholestatic conditions and to create a fundamental base for
developing novel therapeutic strategies for cholangiopathies. The expression of lncRNAs is tissue-, cell type-
and differentiation stage-specific. LncRNA H19 is the first identified imprinted lncRNA and is highly conserved
across lineages. It has been reported that H19 is the most strongly differentially expressed lncRNA during liver
development and has been linked to hepatic metastases from a range of human carcinomas and cholestatic liver
injury. However, the regulatory role of H19 in cholangiocyte pathophysiology remains unknown and is the focus
of the current application. Our most recent studies discovered that H19 is highly expressed in cholangiocytes,
but not in hepatocytes under physiological conditions and hepatic H19 expression levels are correlated with
upregulation of S1PR2 and cholestatic liver injury in the multi-drug resistance 2 knockout (Mdr2-/-) mouse, a well-
established mouse model of PSC and PSC patient liver. Our preliminary data further showed that 1) BDL
significantly up-regulated H19 and down-regulated the apical sodium bile acid transporter (ASBT) and
sodium/taurocholate co-transporting polypeptide (NTCP); 2) BDL-induced cholestatic liver injury was markedly
reduced in H19ΔExon1/+ mouse; 3) Knocking down H19 not only significantly reduced taurocholate (TCA)-
induced expression of fibrotic genes and S1PR2 in cholangiocytes, but also markedly upregulated hepatic small
heterodimer partner (SHP) expression and reduced cholestatic injury in Mdr2-/- mice; 4) Hepatic H19 level was
also significant upregulated in the carbon tetrachloride (CCl4)-induced cholestatic liver injury mouse model.
Based on these observations, we HYPOTHESIZE that lncRNA H19 plays an important role in the regulation
of hepatobiliary epithelial function by disruption of hepatic bile acid homeostasis. Two specific aims are
proposed to test this hypothesis. 1) To define the role of lncRNA H19 in the regulation of bile acid-mediated
cholangiocyte growth and remodeling during cholestatic liver injury; 2) To identify the mechanisms by
which bile acids upregulate lncRNA H19 in cholestatic conditions. Completion of the proposed studies will
make a significant conceptual advance by linking the lncRNA H19-mediated regulation of biliary epithelial
function with cholestatic biliary injury in patients with cholangiopathies and will provide a translational mechanism
for how bile acids and lncRNA H19 mediate hepatobiliary fibrosis.
胆管病,如原发性胆汁性肝硬变(PBC)和原发性硬化性胆管炎(PSC),
以胆管上皮细胞(胆管细胞)的损伤和功能障碍为特征。最近,长时间的非编码
RNAs(LncRNAs)已被确定为一类新的基因表达的主要调控因子,并与
对许多基本的生物过程和各种人类疾病,包括各种肝病。
然而,关于lncRNAs在调节胆管细胞功能和
肝胆疾病的发病机制。当前应用程序的总体目标是确定角色和
LncRNAs在胆汁淤积条件下胆汁功能障碍中的作用机制
为胆管病开发新的治疗策略。LncRNAs的表达是组织、细胞类型的-
和分化阶段特异性。LncRNA h19是第一个被鉴定的印迹lncRNA,高度保守。
跨越血统。据报道,H19是在肝脏中差异表达最强的lncrna。
它与一系列人类癌症和胆汁淤积性肝转移有关
受伤。然而,H19在胆管细胞病理生理中的调节作用尚不清楚,目前仍是研究的焦点。
当前应用程序的。我们最新的研究发现,H19在胆管细胞中高度表达,
而不是在生理条件下的肝细胞中,而肝脏H19的表达水平与
多药耐药2基因敲除(MDR2-/-)小鼠S1PR2表达上调与淤胆性肝损伤
建立PSC小鼠模型和PSC患者肝脏模型。我们的初步数据进一步表明:1)BDL
显著上调H19,下调心尖胆汁酸转运体(ASBT)和
牛磺胆酸钠共转运多肽(NTCP);2)BDL所致的淤胆性肝损伤明显
在H19Δ外显子1/+小鼠中减少;3)击倒H19不仅显著降低牛磺胆酸(Tca)-
诱导肝纤维化基因和S1PR2在胆管细胞中的表达,但也明显上调肝小管上皮细胞
异二聚体伙伴(SHP)的表达与mdr2-/-小鼠的胆汁淤积损伤;4)肝脏H19水平
在四氯化碳(CCl4)诱导的胆汁淤积性肝损伤小鼠模型中也有显著上调。
基于这些观察,我们推测lncrna h19在调控中起重要作用。
通过破坏肝脏胆汁酸平衡来影响肝胆上皮功能。两个具体目标是
提出用来检验这一假说。1)明确lncRNAH19在胆汁酸介导的胆汁酸调节中的作用
胆汁淤积性肝损伤时胆管细胞的生长和重塑;2)探讨其作用机制
哪些胆汁酸在胆汁淤积条件下上调lncRNAH19。建议的研究完成后,
通过连接lncRNA H19介导的胆管上皮调控取得重大概念性进展
胆管病患者胆汁淤积性损伤的功能,并将提供翻译机制
胆汁酸和lncRNAH19如何介导肝胆纤维化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILLIP B HYLEMON其他文献
PHILLIP B HYLEMON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILLIP B HYLEMON', 18)}}的其他基金
LncRNA H19 in Cholestatic Liver Diseases
LncRNA H19 在胆汁淤积性肝病中的作用
- 批准号:
10202570 - 财政年份:2018
- 资助金额:
$ 53.65万 - 项目类别:
LncRNA H19 in Cholestatic Liver Diseases
LncRNA H19 在胆汁淤积性肝病中的作用
- 批准号:
10909545 - 财政年份:2018
- 资助金额:
$ 53.65万 - 项目类别:
Bile Acid and Sphingosine-1-phosphate Receptor-mediated Signaling in Cholestasis
胆汁酸和 1-磷酸鞘氨醇受体介导的胆汁淤积信号传导
- 批准号:
9024718 - 财政年份:2015
- 资助金额:
$ 53.65万 - 项目类别:
Bile Acids and Clostridium scindens Inhibit C. difficile: Role of Secreted Antibacterial Compounds
胆汁酸和梭菌抑制艰难梭菌:分泌的抗菌化合物的作用
- 批准号:
9233344 - 财政年份:2012
- 资助金额:
$ 53.65万 - 项目类别:
Role of Bile Acids and Gut Bacteria in GI Diseases
胆汁酸和肠道细菌在胃肠道疾病中的作用
- 批准号:
8698288 - 财政年份:2012
- 资助金额:
$ 53.65万 - 项目类别:
Role of Bile Acids and Gut Bacteria in GI Diseases
胆汁酸和肠道细菌在胃肠道疾病中的作用
- 批准号:
8536579 - 财政年份:2012
- 资助金额:
$ 53.65万 - 项目类别:
Role of Bile Acids and Gut Bacteria in GI Diseases
胆汁酸和肠道细菌在胃肠道疾病中的作用
- 批准号:
8324091 - 财政年份:2012
- 资助金额:
$ 53.65万 - 项目类别:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
HIV 蛋白酶抑制剂和肝脂质失调
- 批准号:
7035831 - 财政年份:2004
- 资助金额:
$ 53.65万 - 项目类别:
HIV Protease Inhibitors and Hepatic Lipid Dysregulation
HIV 蛋白酶抑制剂和肝脂质失调
- 批准号:
6799002 - 财政年份:2004
- 资助金额:
$ 53.65万 - 项目类别:
相似海外基金
Can circulating bile acids predict knee OA progression?
循环胆汁酸可以预测膝关节 OA 的进展吗?
- 批准号:
10575385 - 财政年份:2023
- 资助金额:
$ 53.65万 - 项目类别:
Preparation of a model animal for progressive familial intrahepatic cholestasis using mice with human bile acids
人胆汁酸小鼠进行性家族性肝内胆汁淤积模型动物的制备
- 批准号:
22K08062 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study of Pathway-Dependent Effects of Luminal Microbial Metabolites Including Short Chain Fatty Acids and Bile Acids in Irritable Bowel Syndrome Through Meta-omics Analysis of Fecal Specimens
通过粪便样本的元组学分析研究肠道微生物代谢物(包括短链脂肪酸和胆汁酸)对肠易激综合征的途径依赖性影响
- 批准号:
10993051 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
The impact of inflammation induced alterations to microbially derived bile acids on susceptibility and severity of Clostridioides difficile infection
炎症诱导的微生物胆汁酸改变对艰难梭菌感染的易感性和严重程度的影响
- 批准号:
10448556 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
The impact of inflammation induced alterations to microbially derived bile acids on susceptibility and severity of Clostridioides difficile infection
炎症诱导的微生物胆汁酸改变对艰难梭菌感染的易感性和严重程度的影响
- 批准号:
10654662 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia
次级胆汁酸在胃食管肿瘤中的作用
- 批准号:
10693227 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
The interaction between gut bacteria in the presence of bile acids
胆汁酸存在下肠道细菌之间的相互作用
- 批准号:
22K05534 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interaction of bile acids and hormone action in the brain
胆汁酸与大脑中激素作用的相互作用
- 批准号:
477275 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
Operating Grants
Study of Pathway-Dependent Effects of Luminal Microbial Metabolites Including Short Chain Fatty Acids and Bile Acids in Irritable Bowel Syndrome Through Meta-omics Analysis of Fecal Specimens
通过粪便样本的元组学分析研究肠道微生物代谢物(包括短链脂肪酸和胆汁酸)对肠易激综合征的途径依赖性影响
- 批准号:
10599335 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别:
The Role of Secondary Bile Acids in Gastro-Esophageal Neoplasia
次级胆汁酸在胃食管肿瘤中的作用
- 批准号:
10506039 - 财政年份:2022
- 资助金额:
$ 53.65万 - 项目类别: